Mutations detected at study start or on study treatment
| Arm/mutation . | Present at study start . | Response on study drug . | Treatment after mutation detection . |
|---|---|---|---|
| Nilotinib | |||
| E450K | Yes | Stable undetectable BCR-ABL1 | Remained on nilotinib |
| Imatinib | |||
| E255K | Yes | Fluctuating BCR-ABL1 levels | Crossed over to nilotinib |
| L248V | Yes | No MMR | Remained on imatinib |
| G250E/F359V | Yes | Loss of CCyR | Crossed over to nilotinib |
| G250E | Yes | Loss of CCyR | Crossed over to nilotinib |
| E453K | No | Loss of CCyR | Crossed over to nilotinib |
| Arm/mutation . | Present at study start . | Response on study drug . | Treatment after mutation detection . |
|---|---|---|---|
| Nilotinib | |||
| E450K | Yes | Stable undetectable BCR-ABL1 | Remained on nilotinib |
| Imatinib | |||
| E255K | Yes | Fluctuating BCR-ABL1 levels | Crossed over to nilotinib |
| L248V | Yes | No MMR | Remained on imatinib |
| G250E/F359V | Yes | Loss of CCyR | Crossed over to nilotinib |
| G250E | Yes | Loss of CCyR | Crossed over to nilotinib |
| E453K | No | Loss of CCyR | Crossed over to nilotinib |